GLP-1 — What Your Prescriber Didn't Tell You

A client came to me recently who had been on semaglutide (Ozempic) for eight months. She had lost 18kg. Her GP was delighted. She was not. Her hair was falling out in handfuls, she could barely tolerate solid food, her energy had collapsed, and she had lost the muscle definition that years of regular training had built. Her blood results, which nobody had checked during the eight months of treatment, told a clear story: ferritin 8 µg/L, B12 214 pmol/L, zinc 9.4 µmol/L, albumin borderline low, HbA1c now well within range but DEXA scan showing significant lean mass reduction alongside the fat loss.

She had achieved what the drug promised. She had also paid a price that her prescriber had not mentioned — because nobody had tested her before she started, nobody had monitored her during treatment, and nobody had considered what would happen to her nutritional status when her appetite was suppressed to the point where she was eating less than 1,000 calories on most days.

This is not an argument against GLP-1 receptor agonists. The evidence that they work is real and compelling. This is an argument for using them with clinical intelligence — testing before, monitoring during, supporting the body through the intervention, and planning for after. The drug does one job very well. The work around it is what determines whether the outcome is genuinely beneficial or temporarily impressive.

What GLP-1 actually is — and what these drugs do to the system

GLP-1 (glucagon-like peptide-1) is an incretin hormone produced by L-cells in the small intestine and colon in response to nutrient arrival. Its natural role is brief and pulsatile: it is released for minutes after a meal, stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and sends satiety signals to the hypothalamus. It is then broken down rapidly by the enzyme DPP-4. The normal half-life of endogenous GLP-1 is approximately 2 minutes.

GLP-1 receptor agonists are synthetic molecules designed to resist DPP-4 breakdown, producing sustained GLP-1 receptor activation for hours or days. Semaglutide (Ozempic, Wegovy) has a half-life of approximately 7 days. Tirzepatide (Mounjaro, Zepbound) activates both GLP-1 and GIP receptors simultaneously. The body goes from receiving brief, meal-triggered pulses of GLP-1 to receiving continuous, supraphysiological stimulation 24 hours a day. The effects are powerful. So are the downstream consequences.

Drug	Brand names	Mechanism	Half-life	Average weight loss
Semaglutide	Ozempic (diabetes) · Wegovy (weight)	GLP-1 receptor agonist	~7 days · weekly injection	15–17% body weight over 68 weeks (STEP trials)
Tirzepatide	Mounjaro (diabetes) · Zepbound (weight)	Dual GLP-1 + GIP receptor agonist	~5 days · weekly injection	20–22% body weight (SURMOUNT trials) — currently highest efficacy available
Liraglutide	Victoza (diabetes) · Saxenda (weight)	GLP-1 receptor agonist	~13 hours · daily injection	8–10% body weight — lower than semaglutide; largely superseded
Dulaglutide	Trulicity	GLP-1 receptor agonist	~5 days · weekly injection	Primarily diabetes management · modest weight effect

The side effects your prescriber should have covered

The clinical trial data on GLP-1 agonists is genuinely impressive for weight loss and glycaemic control. It is less prominently discussed on the adverse effects side — not because the data is absent, but because the headline weight loss numbers dominate the conversation. The following is the clinical picture from the published evidence.

Serious · Muscle Loss

25–40% of weight lost is lean mass

Multiple studies including STEP and SURMOUNT trial analyses show that 25-40% of total weight lost on GLP-1 agonists is lean muscle mass, not fat. This is catastrophic for metabolic health long-term — muscle is the primary site of glucose disposal and the main determinant of resting metabolic rate. Losing it accelerates insulin resistance over the long term even as short-term glycaemic markers improve.

Serious · GI Complications

Gastroparesis — stomach paralysis that can persist

GLP-1 slows gastric emptying as part of its mechanism. Chronic supraphysiological stimulation can produce gastroparesis — significantly delayed gastric emptying — in a subset of users. Cases of gastroparesis persisting for months after drug discontinuation have been reported. Gallbladder disease and gallstones are also significantly elevated (38% increased risk in STEP trials).

Common · GI Symptoms

Nausea, vomiting, diarrhoea — 60-70% of users

GI side effects affect the majority of users, particularly during dose titration. Nausea (44%), diarrhoea (30%), vomiting (24%), constipation (24%). Most reduce over time but rarely disappear entirely. The GI side effect burden is a primary reason 70% of users discontinue within one year.

Important · Nutritional Depletion

Severe deficiencies from appetite suppression

The appetite suppression is powerful enough that many users eat 700-1,000 calories daily — well below the threshold for adequate micronutrient intake regardless of food quality. Protein, zinc, B12, iron, magnesium, and fat-soluble vitamins (A, D, E, K) are all at risk. This is the single most undermonitored clinical consequence of GLP-1 therapy in current UK prescribing practice.

Monitor · Thyroid

Thyroid C-cell tumours — animal data, human uncertainty

Rodent studies showed dose-dependent thyroid C-cell hyperplasia and medullary thyroid carcinoma with GLP-1 agonists. Human data has not confirmed this risk at therapeutic doses, but all GLP-1 agonists carry a black box warning. Contraindicated in those with personal or family history of medullary thyroid carcinoma or MEN2. Baseline calcitonin is recommended by some guidelines before initiation.

Monitor · Rebound

70% weight regain after discontinuation

The STEP 1 extension trial showed that within one year of stopping semaglutide, participants regained two-thirds of lost weight on average. The drug suppresses appetite and slows gastric emptying through continuous receptor activation. When it stops, the receptor activation stops. The underlying metabolic drivers — insulin resistance, dysbiosis, nutrient depletion, HPA dysfunction — that contributed to the original weight gain remain unaddressed.

The Muscle Loss Problem — Why This Matters More Than the Weight Number

25–40%

of weight lost on GLP-1 agonists is lean muscle mass, not fat

Muscle is not cosmetic. It is the primary site of glucose disposal in the body — responsible for approximately 80% of insulin-stimulated glucose uptake. Losing 10kg total on a GLP-1 agonist, with 3-4kg of that being muscle, means the body has reduced its primary glucose-clearing capacity at the same time as its glycaemic markers have improved. The HbA1c looks better. The metabolic architecture is worse. The DEXA scan tells the real story. Almost nobody gets a DEXA scan before or during GLP-1 therapy. This is a significant gap in standard prescribing practice.

What your pancreas was actually trying to tell you

The escalating prevalence of GLP-1 prescribing reflects something real: an epidemic of impaired natural GLP-1 function driven by the modern food environment. Ultra-processed foods, rapid glucose delivery, reduced fibre intake, gut dysbiosis, and chronic stress all impair the L-cell secretion and GLP-1 receptor sensitivity that constitute the natural incretin system.

When someone's post-meal GLP-1 response is blunted, the normal satiety signal after eating is reduced. Gastric emptying is faster than it should be. Insulin secretion is less tightly regulated. Blood sugar rises higher and stays elevated longer. This is not a pharmaceutical deficiency. It is a lifestyle and gut-health-driven functional impairment that pharmacological GLP-1 bypasses rather than addresses.

"A GLP-1 agonist gives you supraphysiological levels of a hormone your gut should be producing naturally. The drug works. But it doesn't fix why the natural system stopped working. That is the conversation that almost never happens at the point of prescribing."

Optimising natural GLP-1 function — the functional medicine approach

Before pharmacological intervention, and as an adjunct to it where drugs are clinically appropriate, the following interventions have evidence for improving endogenous GLP-1 secretion and receptor sensitivity:

Natural GLP-1 Optimisation — Evidence-Based Interventions

These restore the function the drug bypasses — addressing the mechanism, not just the hormone

Resistant starch and dietary fibre — fermented by gut bacteria to short-chain fatty acids (SCFAs), particularly butyrate and propionate, which directly stimulate L-cell GLP-1 secretion. Oats, legumes, cooked-and-cooled potato, green banana.

Protein at breakfast — the most potent meal-timing trigger for GLP-1 release is protein, particularly in the morning. 30-40g protein at the first meal produces a significantly larger GLP-1 response than carbohydrate-dominant breakfast.

Gut microbiome diversity — Lactobacillus and Bifidobacterium populations produce SCFAs that stimulate L-cells. Dysbiosis reduces this. GI-MAP-directed probiotic protocols address the substrate for natural GLP-1 production.

Berberine — activates the same AMPK pathway as metformin and has direct GLP-1 secretagogue activity. Clinical evidence in type 2 diabetes comparable to some pharmaceutical agents. 500mg with meals.

Bitter compounds — bitter taste receptors in the gut wall (TAS2R receptors) stimulate GLP-1 release directly. Dandelion, artichoke, bitter melon, apple cider vinegar pre-meal. This is the clinical basis for digestive bitters beyond their bile-stimulating role.

Blood sugar stabilisation — normalising the glycaemic environment reduces GLP-1 receptor downregulation. Meal sequencing (protein-fat-fibre before carbohydrate), consistent meal timing, and elimination of ultra-processed food improve receptor sensitivity independently of weight.

Sleep quality — single night of sleep deprivation reduces GLP-1 secretion by approximately 20% in controlled studies. Chronic sleep disruption — common in HPA axis dysregulation — chronically impairs the incretin response.

Exercise — specifically resistance training — increases GLP-1 receptor density in skeletal muscle and improves the glucose disposal capacity that GLP-1 is trying to support. The one intervention that simultaneously protects against GLP-1-induced muscle loss and improves the natural incretin system.

What to test before, during, and after GLP-1 therapy

The following testing framework represents the minimum clinical standard for anyone initiating, currently on, or discontinuing GLP-1 receptor agonist therapy. In current UK prescribing practice, most of this is not done.

Timing	Tests	Why
Before starting	Full blood chemistry: HbA1c, fasting insulin, fasting glucose, full lipids, liver enzymes (GGT, ALT, AST), ferritin, B12, folate, zinc, vitamin D, albumin, thyroid panel (TSH + Free T3), calcitonin (if thyroid risk), DEXA if available.	Establishes the baseline metabolic and nutritional picture. Identifies contraindications. Documents starting lean mass. Reveals existing deficiencies that will worsen under appetite suppression.
3 months into treatment	Repeat: ferritin, B12, zinc, albumin, vitamin D. HbA1c and fasting insulin. Liver enzymes. Kidney function (eGFR, creatinine). Body weight AND body composition if possible.	Nutritional depletion is fastest in the first 3 months when appetite suppression is most severe during dose titration. Catching deficiencies early prevents the clinical picture my client presented with at 8 months.
Ongoing (6-monthly)	Full nutritional panel. Muscle mass monitoring — DEXA or at minimum bioimpedance. HbA1c. Liver and kidney function.	Sustained monitoring for cumulative depletion, lean mass loss trajectory, and organ function. Most prescribers do HbA1c only. The nutritional picture requires a separate, deliberate assessment.
Before discontinuing	DUTCH Plus (cortisol pattern, insulin-related markers). Full nutritional panel. GI-MAP (gut microbiome picture). Blood chemistry complete.	Understanding what underlying drivers remain active before stopping — otherwise rebound is almost certain. The gut, the HPA axis, the insulin resistance, the nutritional deficiencies all need to be addressed as part of a planned exit strategy, not discovered after the weight returns.
After stopping	Monthly weight and composition monitoring. Nutritional panel at 3 months. Full metabolic panel at 6 months.	The rebound window. Proactive monitoring allows early intervention if the metabolic picture is deteriorating before significant weight regain has occurred.

The exit strategy — why stopping without a plan produces the worst outcome

The 70% rebound statistic is not a failure of willpower. It is a predictable physiological consequence of removing a continuous GLP-1 receptor activation without having addressed any of the underlying drivers that led to the weight gain in the first place. The drug works as an override. When the override is removed, the underlying system reasserts itself.

A planned exit strategy addresses: the gut microbiome (restore the fibre and fermented food substrate for natural GLP-1 production), the HPA axis (chronic stress drives cortisol-mediated fat storage and appetite dysregulation), insulin resistance (not resolved by weight loss alone — requires dietary structure, exercise, and often targeted supplementation), nutritional repletion (ferritin, B12, zinc, vitamin D all need restoring before discontinuation), and the muscle loss (resistance training during the drug phase, not just after, is the single most important protective intervention).

None of this is complicated. All of it requires planning. Almost none of it happens in standard prescribing consultations.

The Functional Medicine Position on GLP-1 Agonists

These are powerful and effective drugs. The evidence for weight loss and cardiovascular risk reduction is real. The appropriate clinical response is not to dismiss them — it is to use them intelligently. That means testing before, monitoring nutritional status throughout, protecting muscle mass with resistance training, addressing the gut-microbiome substrate for natural incretin function, and planning the exit before initiating. A GP prescribing semaglutide in a ten-minute consultation without baseline bloods, DEXA, or a structured monitoring plan is not practising bad medicine by intention. The prescribing guidelines do not require most of this. The clinical intelligence does.

Get the full metabolic picture before any weight intervention

Whether you are considering GLP-1 therapy, currently on it, or planning to stop — the blood chemistry, DUTCH cortisol pattern, and GI-MAP together give you the complete metabolic and nutritional picture that determines whether the intervention will produce durable results or temporary ones.

Book a Strategy Call →